To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Kristie L. Kahl
Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.
Gina Columbus
Ian W. Flinn, M.D., Ph.D., discusses the use of Copiktra, which was approved in September for patients with relapsed/refractory chronic lymphocytic leukemia.
Kristie L. Kahl
The Food and Drug Administration approved Imbruvica plus Gazyva for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Kristie L. Kahl
In this week’s episode of CURE Talks Cancer, we spoke with two doctors honored for their efforts to improve the quality of life for those affected by chronic lymphocytic leukemia (CLL).
John C. Byrd, M.D.
Will the word "cure" be used for patients with chronic lymphocytic leukemia (CLL)?
Brian Koffman, M.D.C.M
Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones.
Nicole Lamanna, M.D., provides insight on how the management of chronic lymphocytic leukemia (CLL) might progress as new therapeutic agents are introduced or matched together.
In the setting of relapsed chronic lymphocytic leukemia, Nicole Lamanna, M.D., considers the patient and disease factors that affect her selection of therapy.
In the context of therapeutic management of chronic lymphocytic leukemia (CLL), Nicole Lamanna, M.D., offers advice regarding lifestyle modifications that may improve outcomes for patients.
Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other